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We describe a novel infection-responsive coating for urinary catheters that provides a clear visual early
warning of Proteus mirabilis infection and subsequent blockage. The crystalline bioﬁlms of P. mirabilis can
cause serious complications for patients undergoing long-term bladder catheterisation. Healthy urine is
around pH 6, bacterial urease increases urine pH leading to the precipitation of calcium and magnesium
deposits from the urine, resulting in dense crystalline bioﬁlms on the catheter surface that blocks urine
ﬂow. The coating is a dual layered system in which the lower poly(vinyl alcohol) layer contains the self-
quenching dye carboxyﬂuorescein. This is capped by an upper layer of the pH responsive polymer poly
(methyl methacrylate-co-methacrylic acid) (Eudragit S100s). Elevation of urinary pH (4pH 7) dissolves
the Eudragit layer, releasing the dye to provide a clear visual warning of impending blockage. Evaluation
of prototype coatings using a clinically relevant in vitro bladder model system demonstrated that coat-
ings provide up to 12 h advanced warning of blockage, and are stable both in the absence of infection,
and in the presence of species that do not cause catheter blockage. At the present time, there are no
effective methods to control these infections or provide warning of impending catheter blockage.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
It has been estimated that 100 million indwelling urinary
catheters (IUC) are sold annually worldwide (Saint et al., 2000). In
the US alone, 30 million urinary catheters are ﬁtted each year,
making IUCs by far the most commonly deployed medical device,
with levels of use far outstripping other common devices such as
central venous catheters or fracture ﬁxation devices (Darouiche,
2001). Although in many cases the use of IUCs can beneﬁt patients
and greatly aid treatment and recovery, these devices undermine
the innate barriers to bacterial colonisation naturally present in
the urinary tract, thus predisposing patients to infection by ur-
opathogenic bacteria (Stickler and Zimakoff, 1994; Stickler, 2014).
Given the widespread use of these devices, it is perhaps un-
surprising that catheter associated urinary tract infections (CAU-
TIs) are currently among the most common nosocomial infections
in many healthcare settings (Stickler, 2014; Jacobsen et al., 2008;
Tambyah, 2004; Hooton et al., 2010; Getliffe and Newton, 2006).
CAUTIs pose a serious risk to patient welfare and a signiﬁcant ﬁ-
nancial burden to health service providers, exempliﬁed by esti-
mated costs of up to d123 million per annum in the UK, and
$424–451 million per annum in the USA (Jacobsen et al., 2008;r B.V. This is an open access articl
kins).Ploughman et al., 1999).
The problem of CAUTI is particularly pronounced in patients
who are managed long-term with urethral catheterisation, where
IUC are in place for weeks or months at a time. This includes many
elderly individuals and those with spinal cord injuries, in whom
urethral catheterisation is often used to manage incontinence in a
community care setting (Buckley and Lapitan, 2009; Sørbye et al.,
2005; McNulty et al., 2003; Getliffe, 1994). One of the most pro-
blematic and severe complications arising from CAUTI in this
group is the encrustation and blockage of catheters, which may be
experienced by up to 50% of patients undergoing long-term ure-
thral catheterisation (Getliffe, 1994). Encrustation and blockage is
almost exclusively due to infection by Proteus mirabilis, which is
isolated from up to 45% of CAUTIs (Stickler, 2014, 2008; Stickler
et al., 1993; Mobley, 1996). Following the initial colonisation of the
urinary tract, P. mirabilis develops extensive bioﬁlm communities
on catheter surfaces, characterised by aggregations of cells em-
bedded in a dense exopolymeric matrix (Stickler 2014, 2008;
Donlan, 2002). Bioﬁlms are intrinsically resistant to immune
clearance, antimicrobial agents, and environmental factors, hence
treatment of infections involving bioﬁlms is in itself a major
medical problem (Stickler, 2014, 2008; Donlan, 2002). Concurrent
with bioﬁlm development, P. mirabilis expresses a highly potent
urease enzyme during growth in urine, allowing exploitation of
urea as a nitrogen source (Grifﬁth et al., 1976). The activity of thise under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Scheme 1. Urease-catalyserd hydrolysis of urea as a nitrogen source for P. mirabilis.
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pH, and leading to the precipitation of calcium phosphate and
magnesium–ammonium phosphate from urine to form crystals of
carbonate apatite [Ca10(PO4)6CO3], and struvite
(MgNH4PO4 6H2O), respectively (Stickler et al., 1993; Grifﬁth
et al., 1976; Holling et al., 2014a, 2014b). These crystals subse-
quently become incorporated into the developing bioﬁlms, which
further stabilises and enhances their growth (Stickler et al., 1993;
Holling et al., 2014a, 2014b). Through these processes, extensive
abrasive crystalline bioﬁlm structures are formed which encrust
catheter surfaces and eventually block urine ﬂow.
Catheter blockage causes painful retention of urine within the
bladder, and subsequent vesico-ureteric reﬂux of infected urine to
the kidneys (Stickler, 2014; 2008). If blockage is not detected be-
fore this occurs, patients suffer episodes of severe kidney infection
and septicaemia (Stickler, 2014; 2008). Unfortunately, as the ma-
jority of long-term catheterised patients are cared for in the
community, where constant clinical surveillance is not available,
blockage typically remains unnoticed until life threatening con-
sequences arise, and hospital treatment is required Stickler (2014).
Although a range of catheters impregnated with antimicrobials are
widely available, their use in controlling infection even during
short-term catheterisation (o7 days) remains questionable
(Pickard et al., 2012; Morris et al., 1997; Morgan et al. 2009).
Currently, two such “infection control” catheters are available
in the United Kingdom National Health Service: a silver alloy-
coated latex catheter, and a nitrofurazone-impregnated silicone
plastic catheter. However, recent meta-analysis of clinical studies
has shown that silver alloy-coated catheters were unable to sig-
niﬁcantly reduce symptomatic CAUTI compared with standard
catheters, and were considered not to be cost-effective. Nitrofur-
azone-impregnated catheters showed borderline clinical beneﬁt,
however, any beneﬁt was offset by a marked increase in patient
discomfort, and concerns regarding the indiscriminate use of an-
tibiotics (Pickard et al., 2012). Furthermore, all currently available
catheter types remain susceptible to encrustation, including those
with antimicrobial coatings (Stickler, 2014; Pickard et al., 2012;
Morris et al., 1997; Morgan et al., 2009). As such, available infec-
tion control catheters provide little or no beneﬁt for long-term
catherised patients where the onset of bacteriuria (growth of
bacteria in urine) is considered to be almost inevitable (Stickler,
2014; Jacobsen et al., 2008; Kunin, 1997). While bacteriuria andFig. 1. Schematic illustration of dual-layered polymeric architethe majority of CAUTI are asymptomatic and typically not treated,
the serious complications induced by blockage highlight the need
for strategies to better identify and manage P. mirabilis infections,
with the ultimate goal of warning patients and carers that block-
age may be imminent (Stickler, 2014).
The concept of using urinary pH elevation to provide infection
responsive drug release was explored by Irwin et al. (2013), who
successfully achieved controlled release of nalidixic acid from poly
(2-hydroxyethylmethacrylate (p(HEMA)) hydrogels. Here, a novel
“early warning” system is described, which is designed to alert
patients and carers of forthcoming catheter blockage. The system
takes the form of an infection-responsive surface coating, com-
patible with existing catheter designs, able to provide a visual
warning of P. mirabilis infection prior to encrustation and blockage.
The coating consists of a dual-layered polymeric architecture, in
which a lower layer of hydrogel (poly (vinyl-alcohol)) is employed
to encapsulate the self-quenching dye 5(6)-carboxyﬂuorescein, at
concentrations sufﬁcient to inhibit ﬂuorescence. This lower layer is
capped and sealed by an upper pH-sensitive ‘trigger’ layer, en-
suring no dye release while this is in place (Fig. 1). The ‘trigger’
layer is composed of EUDRAGITsS 100 (an anionic co-polymer of
methacrylic acid and methyl methacrylate). Elevation of urinary
pH upon P. mirabilis infection (via the urease-catalysed hydrolysis
of urea) causes dissolution of the upper EUDRAGITsS 100 layer,
releasing the carboxyﬂuorescein contained in the lower hydrogel
matrix to provide a clear visual signal throughout the catheter
drainage system that blockage is imminent, and intervention is
required.2. Experimental section
2.1. Silanisation of Foley catheters
In order to coat the hydrophobic silicone catheter with PVA, it
was necessary to modify the surface with a hydrophilic moiety. In
this case, a silane (3-Aminopropyl triethoxysilane) (APTES) in-
troduced ethoxy groups on the catheter surface. The method for
hydrophilisation of catheter surfaces via silanisation of the silicone
surface was modiﬁed from Gencer et al. (2012). Catheters were
washed in 1:1 mixture of ammonia (33% v/v) and hydrogen per-
oxide (30% v/v) for 10 min with constant shaking, then rinsed with
deionized water and dried under nitrogen. The catheter was then
placed in APTES (1% V/V) dissolved in dry N,N-Dimethylformamide
(DMF) for 16 h. The surface-modiﬁed catheters were subsequently
washed with DMF and dried under nitrogen. Water contact angle
measurements were made to ensure the hydrophilic nature of the
surface.cture for pH-triggered release of 5(6)-carboxyﬂuorescein.
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Poly(vinyl alcohol) (PVA,14,600–18,600 gmol1) (20% w/v) was
dissolved in deionized water and heated to 97 °C with constant
stirring to facilitate dissolution. The cooled solution was stored at
room temperature until required.
2.3. EUDRAGITsS 100 solution preparation
EUDRAGITsS 100 with a ratio of the free carboxyl groups to
ester groups at approximately 1:2, and an average molecular
weight of 150,000 g/mol was used, supplied directly from Evonik
industries, Germnay. The organic dip coating solution of EU-
DRAGITsS 100 was prepared according to the technical informa-
tion (Evonik, 2015). EUDRAGITsS 100 powder was added slowly to
half of the diluent mixture, and stirred for 60 min until the poly-
mer was completely dissolved. To the remaining diluent mixture
was added talc and triethyl citrate, and the resultant suspension
stirred for 10 min with a high shear mixer. The suspension was
poured slowly into the EUDRAGITsS 100 solution with constant
stirring, before being Buchner ﬁltered to remove the talc. The so-
lution was stored at room temperature until required.
2.4. Coating of Foley catheters
To cooled PVA solution (ca. 20 °C) was added 5(6)-carboxy-
ﬂuorescein (CF) solution (500 mM) at a 1:1 ratio. The resultant
solution of hydrogel (10% w/v) containing CF dye (250 mM) was
stored in the dark at room temperature. Catheters were coated
with the gel/dye solution (100 mL) between the retention balloon
and the tip, and stored at 20 °C overnight to promote cryogenic
gelation. Catheters were thawed at room temperature (4 h) before
dip coating with the pH-responsive trigger layer. Catheters were
manually dip-coated 20 times in the EUDRAGITsS 100 solution,
with a 5 min solvent evaporation period at room temperature
between each coating. Coated catheters were stored at 4 °C until
required.
2.5. Artiﬁcial urine preparation
Sterile artiﬁcial urine was produced according to Stickler et al.
(1999). A 5 concentrated stock solution was prepared containing
anhydrous sodium sulphate (11.50 g/L), magnesium chloride hex-
ahydrate (3.25 g/L), sodium chloride (23.00 g/L), tri-sodium citrate
(3.25 g/L), sodium oxalate (0.10 g/L), potassium di-hydrogen or-
thophosphate (14.00 g/L), potassium chloride (8.00 g/L), ammo-
nium chloride (5.00 g/L), gelatin (25.00 g/L) and tryptic soy broth
(5.00 g/L), urea (125 g/L), and calcium chloride (3.25 g/L). Stock
solutions of urea and calcium chloride were sterilised separately
by membrane ﬁltration (0.45 mm; Sartorius, United Kingdom)
while other components were sterilised by autoclaving. For use in
bladder models all components were combined and diluted to 1
strength using sterile deionised water, with the ﬁnal pH adjusted
to 6.1.
2.6. In vitro bladder models
Bladder model setup and operation was followed according
to Stickler et al. (1999). The model consists of double-walled glass
vessel maintained at 37 °C by an external water jacket (Fig. S1).
The model was ﬁrst sterilised by autoclaving, and coated catheters
inserted aseptically into the vessel via silicone tubing attached to a
glass outlet at the base. The catheter retention balloon was inﬂated
using sterile water (10 mL) (achieving the sealing of the bladder
outlet), and the catheter attached to a sterile drainage bag to form
a full sterile closed drainage system. Sterile artiﬁcial urine wassupplied to the bladder model via a peristaltic pump at a ﬂow rate
of 0.75 mL/min. This allows a reservoir (∼30 mL) of urine to collect
in the bladder below the level of the catheter eyehole. As the
volume of supplied urine increases, the overﬂow drains through
the catheter to the collection bag. For bladder models simulating
infection, residual urine in the models was inoculated directly
with P. mirabilis or E. coli bacteria (1010 CFU). Clinical isolates of P.
mirabilis RS1 were obtained from the Royal Sussex County Hos-
pital, and uropathogenic E. coli NSM59 from University Hospitals,
Bristol. Both strains were isolated from urinary tract infections.
The bacterial cultures were allowed to incubate within the bladder
model for 1 h to establish before ﬂow was restored.
2.7. Quantiﬁcation of viable bacterial cells in bladder models
Serial dilutions of the original bladder model culture were
performed and plated on NSLB agar (tryptone (10 g/L), yeast ex-
tract (5 g/L), technical agar (20 g/L)). Each cell present will pro-
liferate to form a visible colony that can be recorded and used to
estimate the number of cells in the original culture, expressed as
colony forming units/mL (CFU/mL).3. Results and discussion
3.1. Infection models for evaluation of coating performance and ca-
theter blockage
To evaluate the ability of the dual-layered “triggered-release”
system to provide advanced warning of P. mirabilis infection and
catheter blockage, the performance of coated catheters was tested
using the in vitro bladder model system, originally described by
Stickler et al. (1999) This model replicates a full sterile closed-
drainage system, as used in clinical practice, providing a good
representation of the in vivo catheterised urinary tract (Fig. S1).
Prototype coatings were applied directly to the top 1 cm of silicone
catheters, above the retention balloon (Bard all-silicone Foley ca-
theters). Once the catheter is ﬁtted, this coated region sits within
the pool of residual urine that forms in the bladder. During in-
fection, this sump of urine acts as a reservoir of bacteria and ty-
pically harbours a high bacterial load. The blockage of catheters
can be readily identiﬁed in the bladder model system by mon-
itoring the ﬂow of urine.
Since changes to catheter surfaces may inﬂuence the rate of
bacterial bioﬁlm formation, it was ﬁrst conﬁrmed that coated ca-
theters did not alter the ability of P. mirabilis to form crystalline
bioﬁlms and block catheters in this system. In models with coated
catheters, P. mirabilis was able to rapidly encrust catheters and
completely block urine ﬂow in an average time of 16 h. This is
comparable to the time taken for the same strain of P. mirabilis to
block uncoated catheters under the same conditions, and no sig-
niﬁcant differences in time to blockage were evident between
models ﬁtted with coated or uncoated catheters (Fig. S2). In
common with previous studies, (Holling et al., 2014a, 2014b) the
encrustation and blockage of catheters in models infected with P.
mirabilis was associated with an increase in urinary pH to an
average of pH 8.55 on blockage. No signiﬁcant differences were
observed in the ability of P. mirabilis to elevate urinary pH or grow
and persist in the system, in models ﬁtted with coated catheters,
compared to models ﬁtted with standard uncoated catheters
(Figure S2).
3.2. Activation of catheter coating and advanced warning of
blockage
In order to evaluate the capacity of the triggered-release
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release of dye and consequent colour change of urine during the
course of bladder model experiments was monitored, and it was
calculated how long before catheter blockage that this signal be-
came apparent (duration of early warning). Since the application
of this technology will be in alerting patients or their carers to the
potential for impending blockage (requiring the signal to be easily
visible without specialist equipment), these experiments were
based on the direct subjective assessment of colour change by eye
alone, under ambient lighting conditions. Observation of dye re-
lease was used to prompt associated quantitative analysis of ur-
inary ﬂuorescence, viable bacterial cell counts and pH of residual
urine, with the blockage of catheters by P. mirabilis taken as the
experimental end-point. In parallel, the response of coatings to
Escherichia coli was also assessed, which is not only the most
commonly encountered pathogen of the urinary tract overall, but
also an example of a urease negative species unable to block or
encrust catheters. Thus, models infected with E. coli served as
additional controls to determine if coatings could discriminate
urease producing P. mirabilis from non-urease producing species,
which is vital for accurate early warning of blockage.
During the experiments, no obvious colour change was ob-
served in models devoid of P. mirabilis. In uninfected models, or
those infected with E. coli, coatings remained intact and no dye
release visible to the naked eye was noted at any point throughout
the experimental procedure (Fig. 2). This highlights the stability of
the coatings in the absence of P. mirabilis infection. However, in
models inoculated with P. mirabilis, a distinct colour change was
observed in urine in bladder models an average of 4.2 h after the
start of experiments. Although clearly visible in residual bladder
urine, at the time of this colour change, the signal was not yet
visible in urine collected in the drainage bag, and colour intensityFig. 2. Example images documenting coating activation during the course of one expe
bacterial species or devoid of bacteria: No infection – Un-inoculated controls devoid of bac
infected with an E. coli clinical isolate (non-urease producing species). Rows show ex
activation: Model start – Images taken at the start of experiments. For Initial and Strong
which colour change was observed, and the standard error of the mean.continued to increase. Colour change in the urine appeared to
reach a maximum intensity an average of 6.2 h after model acti-
vation. At this point, the colour change was clearly visible in urine
accumulating in drainage bags (Fig. 3).
The intensity of the urine colouration reduced slightly over
time, but was visible for the remainder of experiments, including
within urine accumulated in drainage bags, until catheters became
blocked at around 16 h on average. Removal of the Foley catheters
from the control and P. mirabilis infected models 24 h after initial
inoculation (8 h post-blockage), revealed that all encapsulated dye
had been released from the coating in response to P. mirabilis in-
fection, but not from the uninfected control models, which had
remained intact despite constant contact with a ﬂowing liquid
culture.
Dye release and changes in urine colour observed by eye were
correlated with changes in pH of residual bladder urine in P. mir-
abilis infected models (Fig. 4a). A rise in urine pH of 1.2 pH units
(from pH 6.1 to 7.3) was measured at the initial colour change
(around 4 h) and was also evident at the point of strong colour
change (around 6 h), increasing to a maximum of pH 8.6 at
blockage. The measured ﬂuorescence intensity of the bladder ur-
ine (Fig. 4b) in P. mirabilis infected models also corresponded with
the observed dye release shown in Fig. 2. The two controls both
exhibited negligible ﬂuorescence intensity over all time points,
suggesting that the coating was stable in artiﬁcial urine (pH 6.1)
for the duration of these experiments. The P. mirabilis inoculated
model, however, exhibited a large increase in ﬂuorescence (ca. 20
fold) at the point of initial colour change (around 4.2 h) where pH
had risen to 7.3. Fluorescence increased ﬁve times further when
maximum colour change was observed (around 6.2 h), before de-
creasing somewhat by the time catheters had become blocked.
The decrease between the maximum observed colour change atriment. Columns show example images taken from models infected with distinct
teria. P. mirabilis – Models infected with a P. mirabilis clinical isolate. E. coli – Models
ample images of bladder models at key time points related to observed coating
colour change ﬁgures in parentheses provide the average time after model start at
Fig. 3. Visual colour change in urine collection bag in response to P. mirabilis infection. (i) Uninoculated standard catheter control (ii) P. mirabilis inoculated coated catheter
control at 6.2 hours.
Fig. 4. Analysis of in vitro bladder model conditions. (a) pH of residual bladder model urine at model start (0 h), on initial colour change (average 4.2 h), maximal colour
change (average 6.2 h), and on catheter blockage (average 16.1 h) (b) Measured ﬂuorescence of bladder model urine at the same time points. **** po0.0001. Data shown is
the mean of triplicate repeats. Error bars represent standard error of the mean (SEM). For part B only ## po0.01; #### po0.0001P. mirabilis at 0 h vs P. mirabilis at 6.2 h.
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around 16 h, would be due primarily to the dilution effects of
continual urine ﬂow and exhaustion of dye reservoir on the coated
catheter.
Overall, when considered in the context of catheter blockage,
the colour change induced by P. mirabilis activation of our proto-
type coatings provided 10–12 h advanced warning of blockage,
which is sufﬁcient to permit intervention before the occurrence of
any serious complications. A clear indication of P. mirabilis infec-
tion and imminent blockage being visible within accumulated
urine in the drainage bags is also an important feature of the
working system for several reasons: because this may be the only
portion of the closed-drainage system that may be readily ob-
served by patients or carers; and because drainage bags require
regular emptying ensuring that this part of the system will be
frequently checked.
Despite a lack of commercially available solutions for preven-
tion or control of catheter blockage, the targeted detection of early
P. mirabilis colonisation through monitoring of urinary pH has also
been explored by others (Stickler et al., 2006a; Stickler et al.,
2006b; Malic et al., 2012). These studies describe the creation of a
pH sensor based on the incorporation of bromothymol blue into
cellulose acetate or silicon polymers, which may be inserted as a
connector between the drainage bag and catheter, or introducedinto the drainage bag itself.(Stickler et al., 2006a; Stickler et al.,
2006b; Malic et al., 2012) The performance of these sensors in
early lab scale trials (also using the in vitro bladder model system)
compares well to our surface coating and early warning of P.
mirabilis induced blockage of between 12 and 43 h were reported
in different tests (Stickler et al., 2006a; Malic et al., 2012).
Although in some cases a signiﬁcantly greater duration of early
warning was reported compared to our system, this almost cer-
tainly reﬂects the differences in the experimental setup, and the
modelled infection scenario. In studies reporting a greater dura-
tion of early warning (43 h), models were inoculated with far
fewer cells (3 log lower) than used in our experiments, and were
more reﬂective of earlier stages of infection (Stickler et al., 2006a).
As such, overall time to blockage and elevation of urinary pH
would be expected to take commensurately longer to achieve.
However, examination of subsequent iterations of these sensors
employed bladder model experiments more comparable to those
conducted here, and provided early warning in a similar time-
frame to the coating described in this work (Stickler et al., 2006a;
Malic et al., 2012).
Overall, the coating system detailed here appears to perform as
well as the bromothymol blue-based sensor approach, at least in
terms of the in vitro bladder model system. However, the in-
corporation of this functionality into a surface coating applied
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that require the fabrication and use of additional components
within the closed drainage system. The use of an additional
component stands to not only increase the cost of providing this
protection to patients, but also introduces additional complexity
for patients and carers when ﬁtting the system, as well as addi-
tional junctures at which the sterility of the system (the primary
protection for the patient against infection) may be compromised.
Some of these issues were highlighted in subsequent pilot scale
clinical trials of these bromothymol blue based sensor devices that
insert as connectors between catheter and drainage bag tubing
(Long et al., 2014). In this trial some patients and carers reported
issues with leakage, ease of use, and in a few cases that the extra
tubing interfered with the ability to conceal their catheter drai-
nage system (Long et al., 2014).
In contrast, these issues are all negated by the use of a surface
coating approach. This strategy ﬁts well with existing catheter
manufacturing processes, where many variations of catheters with
hydrogel or other surface coatings are already mass produced and
commercially available. Further, the work here shows this is
compatible with existing catheter designs. However, perhaps the
principal advantage of the surface coating approach demonstrated
here is the potential to add further functionality to these systems
by incorporating additional active ingredients into the hydrogel
reservoir. In this scenario, the triggered release and early visual
warning of impending blockage could work in parallel with the
release of antimicrobial agents, such as biocides or bacteriophage,
to actively combat infection and slow or prevent blockage. The
potential for this in comparable triggered release systems in-
tended for application to prototype wound dressings has already
been demonstrated, where virulence factor secretion by promi-
nent wound pathogens can be used to trigger release of bacter-
iophage (Bean et al., 2014), and the enhancement of the catheter
coatings in a similar fashion is also eminently feasible.
It is also important to consider the potential for activation of
the coating by other uropathogens, and the implications of this for
infection control. The lack of coating activity in models infected
with E. coli indicates that our system can discriminate ureolytic
pathogens from non-urease producers. Although P. mirabilis is the
most common cause of catheter blockage, a number of other no-
table pathogens of the catherised urinary tract are urease produ-
cers and these include Pseudomonas aeruginosa, Klebsiella pneu-
moniae, Providencia stuartii, Providencia rettgeri, Morganella mor-
ganii, and P. vulgaris (Stickler, 2008; Broomﬁeld et al., 2009). For
the most part, urease activity in these other species is considerably
less than that exhibited by P. mirabilis, and among these species
only Pr. retgerii, M. morganii, and P. vulgaris have been reported to
elevate urinary pH above pH 7, and to be capable of encrusting
catheters (Broomﬁeld et al., 2009). Because the coating is tuned to
respond to changes in urinary pH, rather than the direct detection
of urease activity or species speciﬁc factors, the coating should also
be able to indicate infection by any species capable of sufﬁciently
elevating urinary pH and causing blockage. This should permit the
early warning of blockage and the need for intervention, regard-
less of the pathogen driving the elevation of urine pH.
The dissolution pH threshold of the trigger layer is also an
important factor in the accuracy of this coating in signalling the
potential for blockage. This requires a balance between providing
an accurate signal of infection associated pH elevation, and pro-
viding a sufﬁcient length of warning in patients where urinary pH
may be more variable. Although uninfected urine typically has pH
ranging from 6.1–6.5, in some cases extremes of pH from a lower
limit of 5.5 to an upper limit 7.0 have been reported (though these
extremes are typically associated with other underlying disorders
(Rose et al., 2015). However, perhaps the more critical value in
terms of catheter blockage is the pH at which crystal formation isinitiated, and this “nucleation” pH can also vary person to person
and has been reported to range from pH 6.57–8.95 (Mathur et al.,
2006). Given the range of values reported for urinary pH and
nucleation pH, the current dissolution threshold of pH 7 would
seem to offer a good compromise between the requirement for
accurate warning and sufﬁcient length of warning, and should be
suitable for the vast majority of catheterised patients. This
threshold is also congruent with levels of pH detected by pre-
viously reported bromothymol blue based pH sensors for mon-
itoring P. mirabilis infection and warning of blockage (Stickler et al.
2006a; Malic et al., 2012). However, the optimisation of this aspect
of coating function will need to be informed by larger scale eva-
luation in bladder models run with urine collected from human
volunteers, and ultimately, clinical trials.4. Conclusion
We have demonstrated a novel and previously unreported
application of a pH-responsive polymer, in a dual-layered surface
coating for urinary catheters. The coating was engineered to pro-
vide a visual response following a pH trigger: which correlates
with an early warning of urinary catheter blockage as a result of P.
mirabilis infection. This system provided a clear and unambiguous
signal of infection throughout the catheter – urine collection bag
closed drainage system, and duration of warning sufﬁcient to
permit intervention and thus potentially to prevent serious clinical
complications. Performance was comparable to other reported
sensor systems for early warning of blockage, which work on si-
milar principles, although the implementation of this approach as
a surface coating holds considerable manufacturing and practical
advantages. Collectively, this work provides sound proof-of-con-
cept for this infection-responsive surface technology and a ﬁrm
foundation for its further optimisation and development, parti-
cularly in terms of increasing functionality through inclusion of
antimicrobial agents. The diagnostic (and potentially theranostic)
system described in this work has the potential to have a sig-
niﬁcant positive impact on patient welfare, and also reduce the
cost of care, through prevention of catheter blockage and asso-
ciated complications.Acknowledgements
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